The deal, officially announced today (21 Feb 2020), enhances Kerry’s position in the hydrolysed plant protein space for specialised nutrition, and expands its capacity in the rapidly growing, high-quality, organic plant protein market.
In a press release Kerry said the growing demand for natural and plant-based products from consumers has been fueling explosive demand for plant-based proteins and foods in recent years.
Indeed, as consumers reduce consumption of dairy and soya proteins, rice and pea protein have become two of the fastest-growing plant protein segments globally, it said, noting that the global plant proteins ingredient market is projected to grow at 6.6% per year between 2018 and 2023.
Seville-based Pevesa Biotech is a leader in non-allergenic, non-GMO plant proteins for the infant, general and clinical nutrition markets. The company supplies a range of high-quality plant proteins, including organic pea and rice protein and protein hydrolysates and is a European leader in non-allergenic plant proteins for infant nutrition.
The company has also developed a range of organic and standard biofertilizers for fruit, olive and specialist garden growers, and has had a strong corporate focus for many years on developing sustainable solutions to important nutrition, health, biowaste and agricultural challenges.
“Kerry is extremely pleased to bring the global expertise of Pevesa into our leading plant protein portfolio,” commented John Reilly, VP Business Development Proteins, Kerry. “Kerry was attracted to Pevesa because of its expertise, innovation, high-quality manufacturing leadership, and patented technology in the non-allergenic plant protein market.”
“This will be a good fit with Kerry’s growing plant protein product portfolio, and Pevesa’s customers will benefit from the synergy between its market-leading technology and Kerry’s protein processing expertise.”